Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 14/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 9/20 | 0.59 |
| ▸ | PDE5A | O76074 | 1/20 | 0.49 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5713135 | 0.89 | PDE5A (0.60) | PTGS2PTGS1PDE5APRKCZ | |
| SCHEMBL5693452 | 0.87 | PTGS2 (0.64) | PTGS2PTGS1PDE5APRKCZ | |
| SCHEMBL5693253 | 0.85 | PTGS2 (0.71) | PTGS2PTGS1PDE5APRKCZ | |
| SCHEMBL5693277 | 0.85 | PTGS2 (0.71) | PTGS2PTGS1PDE5APRKCZ | |
| SCHEMBL5693347 | 0.83 | PTGS2 (0.66) | PTGS2PTGS1PDE5APRKCZ | |
| SCHEMBL17158160 | 0.83 | PTGS2 (0.46) | PTGS2PTGS1PDE5APRKCZ | |
| SCHEMBL5713114 | 0.83 | PRKCZ (0.43) | PTGS2PTGS1PDE5APRKCZ | |
| SCHEMBL5693301 | 0.83 | PTGS2 (0.59) | PTGS2PTGS1PDE5A | |
| SCHEMBL5693239 | 0.82 | PTGS2 (0.58) | PTGS2PTGS1PDE5A | |
| SCHEMBL17158056 | 0.81 | PTGS2 (0.42) | PTGS2PTGS1PDE5APRKCZ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1384477-B1 | UTILIZATION OF PYRAZOLINE DERIVATIVES IN THE PREPARATION OF A MEDICAMENT FOR THE PREVENTION AND/OR TREATMENT OF PROLIFERATIVE CELL DISEASES | ESTEVE LABOR DR (ES) | 2006-05-24 | — | — | EP | claimed |
| US-RE38963-E1 | Pyrazoline derivatives, their preparation and application as medicaments | LABORATORIOS DEL DR. ESTEVE (ES) | 2006-01-31 | — | — | US | claimed |
| EP-1083171-B1 | PYRAZOLINE DERIVATIVES, THEIR PREPARATION AND APPLICATION AS MEDICAMENTS | ESTEVE LABOR DR (ES) | 2004-04-28 | — | — | EP | claimed |
| US-20040034082-A1 | Utilization of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of proliferative cell diseases | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2004-02-19 | — | — | US | claimed |
| EP-1384477-A1 | UTILIZATION OF PYRAZOLINE DERIVATIVES IN THE PREPARATION OF A MEDICAMENT FOR THE PREVENTION AND/OR TREATMENT OF PROLIFERATIVE CELL DISEASES | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2004-01-28 | — | — | EP | claimed |
| US-6353117-B1 | ANTIINFLAMMATORY ACTIVITY AND DISEASES IN WHICH CYCLOOXYGENASE-2 PLAYS A PART, WITHOUT HAVING THE GASTRIC AND RENAL TOXICITY OF THE CLASSIC NONSTEROIDAL ANTIINFLAMMATORY AGENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2002-03-05 | — | — | US | claimed |
| EP-1083171-A1 | PYRAZOLINE DERIVATIVES, THEIR PREPARATION AND APPLICATION AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2001-03-14 | — | — | EP | claimed |
| EP-1408035-B1 | METHOD OF PREPARING DERIVATIVES OF 1.5-DIARYL-3-TRIFLUOROMETHYL-DELTA2-PYRAZOLINES THAT ARE RACEMIC AND ENANTIOMERICALLY PURE | ESTEVE LABOR DR (ES) | 2006-01-04 | — | — | EP | disclosed |
| US-6958403-B2 | Procedure for the preparation of racemic and enantiomerically pure derivatives of 1,5 diaryl-3-trifluorromethyl-Δ2-pyrazolines | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2005-10-25 | — | — | US | disclosed |
| US-20050096373-A1 | Procedure for the preparation of racemic and enantiomerically pure derivatives O F 1,5 diaryl-3-trifluorromethyl-delta2-pyrazolines | LABORATORIES DEL DR. ESTEVE, S.A. | 2005-05-05 | — | — | US | disclosed |
| US-20050096474-A1 | Procedure for the preparation of racemic derivatives of 1,5-diaryl-3-trifluoromethyl-delta2-pyrazolines | LABORATORIES DEL DR. ESTEVE, S.A. | 2005-05-05 | — | — | US | disclosed |
| US-6846935-B2 | Procedure for the preparation of racemic and enantionmerically pure derivatives of 1,5-diaryl-3-trifluoromethyl-Δ2-pyrazolines | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2005-01-25 | — | — | US | disclosed |
| EP-1408035-A1 | METHOD OF PREPARING DERIVATIVES OF 1.5-DIARYL-3-TRIFLUOROMETHYL-DELTA2-PYRAZOLINES THAT ARE RACEMIC AND ENANTIOMERICALLY PURE | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2004-04-14 | — | — | EP | disclosed |
| US-20040019222-A1 | Method of preparing derivatives of 1,5-diaryl-3-trifluoromethyl-delta2-pyrazolines that are racemic and enantiomerically pure | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096474-A1 | Procedure for the preparation of racemic derivatives of 1,5-diaryl-3-trifluoromethyl-delta2-pyrazolines | CLIC1, PEAK1, SIGMAR1 | PTGS2 3685/4885PTGS1 1307/4885PDE5A 1356/4885 |
| US-20040034082-A1 | Utilization of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of proliferative cell diseases | VHL, MET, PRMT1 | PTGS2 3894/4885PTGS1 1996/4885PDE5A 4420/4885 |
| US-20040019222-A1 | Method of preparing derivatives of 1,5-diaryl-3-trifluoromethyl-delta2-pyrazolines that are racemic and enantiomerically pure | CLIC1, SRD5A1, PEAK1 | PTGS2 3156/4885PTGS1 1227/4885PDE5A 1166/4885 |
| US-20050096373-A1 | Procedure for the preparation of racemic and enantiomerically pure derivatives O F 1,5 diaryl-3-trifluorromethyl-delta2-pyrazolines | CLIC1, SRD5A1, PEAK1 | PTGS2 3711/4885PTGS1 1253/4885PDE5A 1483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.